11¿ù 6ÀÏ (±Ý) |
09:45 |
10:00 |
Àλ縻 |
´ëÇÑÇ÷¾×ÇÐȸ ȸ Àå À±¼º¼ö ÀÌ»çÀå ÀÌÁ¦È¯ |
10:00 |
12:00 |
´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ |
|
|
|
Session I: Microenvironment and immune landscape in multiple myeloma |
ÁÂÀå : ÀÌÁ¦Áß |
10:00 |
10:30 |
Role of microenvironment in the pathogenesis of multiple myeloma |
±è¸í½Å(°¡Å縯ÀÇ´ë) |
10:30 |
11:00 |
Immune landscape in multiple myeloma |
°í¿µÀÏ(¼¿ïÀÇ´ë) |
|
|
Session II: Treatment of transplant-eligible multiple myeloma |
ÁÂÀå : ¹Îâ±â |
11:00 |
11:30 |
Evolving therapeutic options in the induction treatment for transplant-eligible multiple myeloma |
Á¶Àçö(¿ï»êÀÇ´ë) |
11:30 |
12:00 |
Role of autologous stem cell transplant in elderly patients and post-transplant therapeutic options |
¾öÇö¼®(±¹¸³¾Ï¼¾ÅÍ) |
12:00 |
13:00 |
Á¡½É |
13:00 |
15:00 |
°ñ¼öÁõ½ÄÁ¾¾ç¿¬±¸È¸ |
|
13:00 |
13:30 |
Diagnostic workflow for erythrocytosis and thrombocytosis |
¼ºÈÁ¤(°í·ÁÀÇ´ë) |
13:30 |
14:00 |
Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN |
À̼ºÀº(°¡Å縯ÀÇ´ë) |
14:00 |
14:30 |
Post-ET/PV Myelofibrosis vs Primary Myelofibrosis |
±è¹Î°æ(¿µ³²ÀÇ´ë) |
14:30 |
15:00 |
A significance of hydroxyurea resistance in MPN patients |
±è¼º¿ë(°Ç±¹ÀÇ´ë) |
11:30 |
12:00 |
The role of interferon in MPNs |
À±¼®À±(¼øõÇâÀÇ´ë) |
15:00 |
15:15 |
ÈÞ½Ä |
15:15 |
18:15 |
¼ºÀÎ/¼Ò¾ÆALL ¿¬±¸È¸ |
|
|
|
Important but unsolved issues in adult ALL |
ÁÂÀå : µµ¿µ·Ï |
15:15 |
15:45 |
Molecular genetics in adult B-cell ALL |
Á¤¼ºÈÆ(Àü³²ÀÇ´ë) |
15:45 |
16:15 |
Molecular genetics in adult T-cell ALL |
À±ÀçÈ£(°¡Å縯ÀÇ´ë) |
16:15 |
16:45 |
Treatment of relapsed/refractory T-ALL in adult patients |
¹éµ¿¿ø(°æºÏÀÇ´ë) |
16:45 |
17:00 |
NGS MRD ±â¹Ý ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ´Ù±â°ü ¿¬±¸°èȹ |
ÃÖÁ¤À±(¼¿ïÀÇ´ë) |
17:00 |
17:15 |
NGS MRD ºÐ¼®¹æ¹ý 1 |
±è¸í½Å(°¡Å縯ÀÇ´ë) |
17:15 |
17:30 |
NGS MRD ºÐ¼®¹æ¹ý 2 |
¼º¹®¿ì(¼¿ïÀÇ´ë) |
17:30 |
17:45 |
NGS MRD ºÐ¼®¹æ¹ý 3 |
À̽ÂÅÂ(¿¬¼¼ÀÇ´ë) |
17:45 |
18:15 |
ÆгÎÅäÀÇ |
|
11¿ù 07ÀÏ (Åä¿äÀÏ) |
09:00 |
10:00 |
ÆòÀÇ¿øȸ(¿Â¶óÀÎ) |
10:00 |
12:00 |
AML/MDS¿¬±¸È¸ |
|
|
|
Gap & perspective of targeted therapies for AML/MDS |
ÁÂÀå : ±èÇüÁØ/Á¤ÁØ¿ø |
10:00 |
10:30 |
FLT3 inhibitors & Bcl-2 inhibitor for adult AML |
Á¤ÁØ¿ø(¿¬¼¼ÀÇ´ë) |
10:30 |
11:00 |
Targeting gene mutations and epigenetic regulators for pediatric AML |
À¯°ÇÈñ(¼º±Õ°üÀÇ´ë) |
11:00 |
11:30 |
What comes next to HMA for MDS? |
±èÀ¯Áø(°¡Å縯ÀÇ´ë) |
11:30 |
12:00 |
Multi parameterflow cytometry for AML/MDS |
¼ÛÀç¿ì(¿¬¼¼ÀÇ´ë) |
11¿ù 6ÀÏ (±Ý) |
09:45 |
10:00 |
Àλ縻 |
´ëÇÑÇ÷¾×ÇÐȸ ȸ Àå À±¼º¼ö ÀÌ»çÀå ÀÌÁ¦È¯ |
10:00 |
12:00 |
ÀûÇ÷±¸Áúȯ¿¬±¸È¸ |
|
10:00 |
10:05 |
(10:00-10:05) À§¿øÀå Àλ縻 & ¼Ò°³ |
ÀûÇ÷±¸Áúȯ¿¬±¸È¸ À§¿øÀå ÃÖÇü¼ö |
|
|
Session I |
ÁÂÀå : ÃÖÇü¼ö/Á¤Çý¸² |
10:05 |
10:20 |
¼±Ãµ¿ëÇ÷ºóÇ÷ÀÇ epidemiology study °æÇè°ú °³¼±¹æÇâ |
½É¿¹Áö(°è¸íÀÇ´ë) |
10:20 |
10:35 |
¼±Ãµ¿ëÇ÷ºóÇ÷ ȤÀº ¼±ÃµºóÇ÷ÀÇ ±¹³» Registry ±¸ÃàÀÇ Çʿ伺 |
ÃÖÈñ¿ø(µ¿¾ÆÀÇ´ë) |
|
|
Session II |
ÁÂÀå : ÇÑÁø¿µ |
10:35 |
11:05 |
NGS¸¦ È°¿ëÇÑ ºóÇ÷ÀÇ Áø´Ü |
Ȳ»ó¹Ì(¼¿ïÀÇ´ë) |
11:05 |
11:10 |
Áú¹® & discussion |
|
|
|
Session III |
ÁÂÀå : ÇÏÁ¤¿Á/±èÀÎÈ£ |
11:10 |
11:30 |
Autoimmune hemolytic anemia ¼ºÀο¡¼ÀÇ °æÇè |
¼ÛÀÍÂù(Ãæ³²ÀÇ´ë) |
11:30 |
11:50 |
Autoimmune hemolytic anemia ¼Ò¾Æ¿¡¼ÀÇ °æÇè |
ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë) |
11:50 |
12:00 |
Áú¹® & discussion |
|
12:00 |
13:00 |
Á¡½É |
13:00 |
15:00 |
Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ |
|
13:00 |
13:05 |
Opening remarks |
Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ À§¿øÀå ÀÓÈ£ÁØ |
|
|
Session I: Recent updates in LCH |
ÁÂÀå : ¼Á¾Áø |
13:05 |
13:25 |
Updates on target agents of LCH |
Çѽ¹Î(¿¬¼¼ÀÇ´ë) |
13:25 |
13:45 |
CNS LCH |
È«°æÅÃ(¼¿ïÀÇ´ë) |
|
|
Session II: Recent updates in HLH |
ÁÂÀå : À¯Ã¶ÁÖ |
13:45 |
14:05 |
Updates on target agents of HLH |
ÀÌÀç¿í(°¡Å縯ÀÇ´ë) |
14:05 |
14:25 |
Understanding of MAS |
ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë) |
14:25 |
14:45 |
Real world experience for haploidentical HSCT in HLH |
ÀÓÈ£ÁØ(¿ï»êÀÇ´ë) |
14:45 |
14:50 |
Closing remarks |
Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ À§¿øÀå ÀÓÈ£ÁØ |
15:00 |
15:15 |
ÈÞ½Ä |
15:15 |
18:15 |
Ç÷ÀüÁöÇ÷¿¬±¸È¸ |
|
15:15 |
15:20 |
Opening remarks |
|
|
|
Session I: : Pregnancy |
ÁÂÀå : ¿Àµµ¿¬/±èÁø¼® |
15:20 |
15:40 |
Obstetric issues in bleeding disorders |
À¯ÄèÇÑ(°¡ÃµÀÇ´ë) |
15:40 |
16:00 |
Obstetric issues in thrombophilic conditions (IVF µî Æ÷ÇÔ) |
¾È¼¿¬(Àü³²ÀÇ´ë) |
16:00 |
16:10 |
Session Q&A |
|
16:10 |
16:20 |
ÈÞ½Ä |
|
|
Session II: Bleeding disorders |
ÁÂÀå : ¹æ¼ö¹Ì/±è¼ºÇö |
16:20 |
16:40 |
Congenital bleeding disorder |
ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë) |
16:40 |
17:00 |
Acquired hemophilia |
Çö½Å¿µ(¿¬¼¼ÀÇ´ë) |
17:00 |
17:10 |
Session Q&A |
|
17:10 |
17:15 |
Closing remarks |
11¿ù 07ÀÏ (Åä¿äÀÏ) |
09:00 |
10:00 |
ÆòÀÇ¿øȸ(¿Â¶óÀÎ) |
10:00 |
12:00 |
Ç÷¿ìº´¿¬±¸È¸ |
|
10:00 |
10:25 |
Novel agents and current treatment changes in hemophilia : Emicizumab |
ÇÑÁ¤¿ì(¿¬¼¼ÀÇ´ë) |
10:25 |
10:50 |
Novel therapeutics and current treatment changes in hemophilia : Fitusiran, anti-TFPI and gene therapy |
¹Ú¿µ½Ç(°æÈñÀÇ´ë) |
10:50 |
10:55 |
Questions/Answers and Discussion (I) |
|
10:55 |
11:20 |
Multidisciplinary clinic and role of the hematologist : Hemostatic support for the management in the multidisciplinary clinics |
¹éÈñÁ¶(Àü³²ÀÇ´ë) |
11:20 |
11:45 |
Recent update on the clinical guideline for hemophilia |
ÃÖÀºÁø(´ë±¸°¡Å縯ÀÇ´ë) |
11:45 |
11:50 |
Questions/answers and discussion |
|
11:50 |
12:00 |
ÃÑȸ (¿Â¶óÀÎ) |